FibroGen, Inc.

Overview

FibroGen, Inc. is a biopharmaceutical company based in San Francisco, California, founded in 1993. The company focuses on discovering, developing, and commercializing innovative therapeutics for serious medical needs, particularly in oncology and anemia-related conditions. It utilizes advanced science, including hypoxia-inducible factor (HIF) biology, to create first-in-class medicines aimed at treating life-threatening diseases such as metastatic pancreatic cancer and anemia associated with chronic kidney disease.

The lead product, Roxadustat, is an oral small molecule approved in multiple countries for treating anemia in chronic kidney disease patients. The company is also developing monoclonal antibodies FG-3165 and FG-3175 for solid tumors and has plans for Pamrevlumab, which represents a strategic shift in its therapeutic focus. FibroGen collaborates with major pharmaceutical firms like AstraZeneca and Regeneron Pharmaceuticals to advance its research and clinical trials, enhancing its global market presence.

Basic Information

Contact Details

• Phone: +1 415-978-1200
• Website: fibrogen.com
• LinkedIn: linkedin.com/company/fibrogen

Key Focus Areas & Initiatives

• Anemia therapy and research
• Development of Roxadustat for chronic kidney disease
• Oncology therapeutics, including treatments for metastatic pancreatic cancer and solid tumors
• Advancements using hypoxia-inducible factor (HIF) biology
• Collaborative clinical research with major pharmaceutical firms
• Development of monoclonal antibodies FG-3165 and FG-3175
• Development and launch of Pamrevlumab
• Strategic pharmaceutical partnerships
• Biotech innovation and regulatory approvals
• Market expansion in biopharmaceutical research

Technologies Used

• AI
• Atlassian Cloud
• Barracuda Networks
• CloudFlare Hosting
• Cloudflare DNS
• OneTrust
• Outlook
• React
• Remote
• Workday

Affiliated Organizations & Regional Branches

• angel.co/fibrogen
• facebook.com/people/FibroGen-Inc/100066547672274/
• twitter.com/FibroGenInc